Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Emavusertib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Curis Closes Private Placement for Up to $80.8M in Gross Proceeds
    Curis Closes Private Placement for Up to $80.8M in Gross Proceeds

    10 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/curis-announces-closing-of-private-placement-totaling-up-to-80-8-million-in-gross-proceeds-302657173.html

    PR NEWSWIRE
    10 Jan 2026
    Share Share
    Curis to Host Conference Call and Webcast on November 6, 2025
    Curis to Host Conference Call and Webcast on November 6, 2025

    30 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/curis-to-report-third-quarter-2025-financial-and-operating-results-and-host-conference-call-and-webcast-on-november-6-2025-302600252.html

    PR NEWSWIRE
    30 Oct 2025
    Share Share
    Curis Discloses Inducement Grants Per NASDAQ LR 5635(C)(4)
    Curis Discloses Inducement Grants Per NASDAQ LR 5635(C)(4)

    03 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/curis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302575015.html

    PR NEWSWIRE
    03 Oct 2025
    Share Share
    Curis to Present at Upcoming Healthcare Conferences in September
    Curis to Present at Upcoming Healthcare Conferences in September

    02 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/curis-to-present-at-upcoming-healthcare-conferences-in-september-302543939.html

    PR NEWSWIRE
    02 Sep 2025
    Share Share
    Curis Enters into Agreement for Emavusertib Combination Study in Melanoma
    Curis Enters into Agreement for Emavusertib Combination Study in Melanoma

    05 Dec 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/curis-enters-into-agreement-for-emavusertib--pembrolizumab-combination-study-in-melanoma-302005577.html

    PR NEWSWIRE
    05 Dec 2023
    Share Share
    FDA lifts partial hold on Curis' PhI/II leukemia study as biotech raises $15M 
    FDA lifts partial hold on Curis' PhI/II leukemia study as biotech raises $15M 

    07 Jul 2023

    // Paul Schloesser ENDPTS

    https://endpts.com/fda-lifts-partial-hold-on-curis-phi-ii-leukemia-study-as-biotech-raises-15m/

    Paul Schloesser ENDPTS
    07 Jul 2023
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.